Target Translation Consortium: Call for Targets 2020

​

Objective

The Target Translation Consortium (TTC) brings together the resources and expertise of Singapore's public research performers to facilitate the preclinical validation of early drug targets arising from publicly-funded research.

They aim to inform investigators earlier and better about the drug development potential of their proposed target, by helping investigators to:

• Establish a strong causal link between the target and disease pathogenesis

• Demonstrate that target modulation results in the desired therapeutic effect

This enhances opportunities for future funding or partnership opportunities around these targets and increases the chances for success in drug discovery.

TTC is looking for potential drug targets in all therapeutic areas, identified by academic researchers in Singapore.

• The proposed target or approach* should be original and should address an unmet medical need. (*Therapeutic repurposing approaches will also be accepted.)

• The proposal should include initial data suggesting a causativeor promoting role of the target in a human disease.

• All proposed therapeutic modalities (small molecules, biologics, cell/gene/immuno therapy, protein degradation approaches and others) will be accepted for consideration.

Funding Details

Selected projects will benefit from

• Collaboration with drug discovery specialists* to define critical "killer" experiments in order to preclinically validate/ invalidate the proposed target or approach.

• Public research expertise and capabilities that can progress the project will be identified and offered for the investigator's consideration.

• Seed funding which will be provided to cover costs of consumables and services for these "killer" experiments. Funding quantum can vary depending on experimental needs.

*Drug Discovery Specialists are scientists with drug discovery experience.

Eligibility Criteria

All SingHealth researchers are welcome to apply.

• Researchers should have relevant scientific or technical background to drive the proposed project.

• Early career researchers are welcome to apply.

Submission

1. Applicants are to submit their completed proposal 'ttc_proposal-form-v2020_30062020' to Jenefer Alam from SingHealth Intellectual Property Office, SHIP (jenefer.alam@singhealth.com.sg) through Host Institution's Research Office for initial pre-consultation by 27 July 2020, 5pm.

2. Applicants will receive pre-consultation feedback from SHIP on the proposal through Host Institution's Research Office for revision. SHIP may connect the applicants to TTC at ttc@drugtargets.sg for more guidance in preparing their proposals, if required.

3. Please note that SHIP is the institution's TTC representative for SingHealth cluster institutions. SHIP will assist to submit proposals to TTC by 12 August 2020.

Note: SingHealth PIs are to please refer to your respective Institutional Research Administrators for guidance on internal deadlines and submission procedures set by your institutions. 

Contact Person in SHIP

Jenefer Alam

Email: jenefer.alam@singhealth.com.sg

OR

Email: SHIP@singhealth.com.sg

Contact Person in TTC

TTC Liaison Team

Email: ttc@drugtargets.sg

Additional Information

TTC's website:here

 ttc_proposal-form-v2020_30062020.docx